Inhibrx, Inc.

Equities

INBX

US45720L1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 03:58:00 2024-05-30 am EDT			5-day change	1st Jan Change
34.11 ^USD	+0.09%		-0.70%	-10.24%

May. 31	Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index	CI
May. 31	Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Inhibrx, Inc.

Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index	May. 30	CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index	May. 30	CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P TMI Index	May. 30	CI
Sanofi Closes Purchase of US Biotech Company Inhibrx	May. 30	MT
Sanofi: acquisition of Inhibrx finalized	May. 30	CF
Inhibrx, Inc. completed the Spin-Off of 92% stake in Inhibrx Biosciences, Inc..	May. 29	CI
Aventis Inc. completed the acquisition of Inhibrx, Inc. from a group of shareholders.	May. 29	CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index	May. 28	CI
Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi	May. 24	MT
Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Inhibrx Shares Fall After Q4 Net Loss Widens	Feb. 28	MT
Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M	Feb. 28	MT
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Inhibrx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Arecor Therapeutics hails Arestat as 2023 performance "strong"	Feb. 01	AN
North American Morning Briefing : S&P 500 Futures Point to Fresh Record on Netflix Results	Jan. 24	DJ
Health Care Flat After J&J Earnings -- Health Care Roundup	Jan. 23	DJ
Arecor pleased as investee Inhibrx sells therapy to Sanofi	Jan. 23	AN
Sector Update: Health Care Stocks Decline Late Afternoon	Jan. 23	MT
Sector Update: Health Care	Jan. 23	MT
Sanofi Agrees to Buy Inhibrx' Rare Disease Candidate For Up To $2.2 Billion	Jan. 23	MT
CAC40: slight decline in the absence of catalysts	Jan. 23	CF
CAC40: down in the wake of Bunds and US T-Bonds	Jan. 23	CF
News Highlights : Top Company News of the Day - Tuesday at 11 AM ET	Jan. 23	DJ
CAC40: falls back below 7,400, Wall-Street reopens unchanged	Jan. 23	CF

Chart Inhibrx, Inc.

Duration

Period

More charts

Company Profile

Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is a wholly owned subsidiary of Sanofi S.A.

Sector

Biotechnology & Medical Research

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

34.11 USD

Average target price

35.5 USD

Spread / Average Target

+4.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INHIBRX, INC.	-10.24%	1.79B
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs